Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Sunlenca

Sunlenca 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 24–25

HOS-148345 · Präparat HOS-099874

24 Medicinal product by therapeutic Effects on concentrations. Recommendation concerning areas Mean percent change in AUC, co-administration with Sunlenca Cmax Rivaroxaban Plasma concentration of DOAC required. Consult the Summary of Dabigatran may be increased when Product Characteristics of the Edoxaban co-administered with lenacapavir. DOAC for further information on use in combination with moderate CYP3A inhibitors and/or P-gp inhibitors. ANTIFUNGALS Voriconazolea,b,p,q (400 mg twice Lenacapavir: No dose adjustment of lenacapavir daily/200 mg twice daily) AUC:↑ 41% is required. Cmax:↔ Itraconazole Interaction not studied. Ketoconazole Plasma concentration of lenacapavir may be increased when co-administered with itraconazole or ketoconazole. H2-RECEPTOR ANTAGONISTS Famotidinea,b (40 mg once daily, 2 Famotidine: No dose adjustment of famotidine hours before lenacapavir) AUC:↑ 28% is required. Cmax:↔ ORAL CONTRACEPTIVES Ethinylestradiol Interaction not studied. No dose adjustment of Progestins ethinylestradiol and progestins is Plasma concentrations of required. ethinylestradiol and progestins may be increased when co-administered with lenacapavir. GENDER AFFIRMING HORMONES 17β-estradiol Interaction not studied. No dose adjustment of these gender Anti-androgens affirming hormones is required. Progestogen Plasma concentrations of these Testosterone medicinal products may be increased when co-administered with lenacapavir. a Fasted. b This study was conducted using lenacapavir 300 mg single dose administered orally. c Evaluated as a strong inducer of CYP3A, and an inducer of P-gp and UGT. d Fed. e Evaluated as a strong inhibitor of CYP3A, and an inhibitor UGT1A1 and P-gp. f Evaluated as a moderate inducer of CYP3A and an inducer of P-gp. g Evaluated as a strong inhibitor of CYP3A and an inhibitor of P-gp. h Evaluated as a strong inhibitor of CYP3A, and an inhibitor and inducer of P-gp. i This study was conducted using lenacapavir 600 mg single dose following a loading regimen of 600 mg twice daily for 2 days, single 600 mg doses of lenacapavir were administered with each co-administered medicinal product. j Evaluated as a P-gp substrate. k Tenofovir alafenamide is converted to tenofovir in vivo. l Evaluated as an OATP substrate. m Evaluated as an BCRP substrate. n Evaluated as a CYP3A substrate. o Major active metabolite of midazolam. p Evaluated as a strong inhibitor of CYP3A. q This study was conducted using voriconazole 400 mg loading dose twice daily for a day, followed by 200 mg maintenance dose twice daily.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) ketoconazole (HOS-084513) tenofovir alafenamide (HOS-110476) estradiol (HOS-090751) famotidine (HOS-112087) dabigatran (HOS-112096) rivaroxaban (HOS-086236) voriconazole (HOS-084524) itraconazole (HOS-084516) testosterone (HOS-144014) edoxaban (HOS-086234) midazolam (HOS-086167)